Similar Items: Obstacles and solutions for implementing amyloid‐targeting treatments in Europe
- Performing multiple biomarker tests delays initiation of amyloid‐targeting treatments
- Identification of patients receiving amyloid‐targeting therapies in observational studies using amyloid PET trajectories: Insights from LEADS
- Travel barriers to amyloid‐targeting infusion access among older adults
- Eligibility for anti‐amyloid treatment in a multiethnic community‐based study
- Clinical and MRI features associated with amyloid positivity in secondary screening for anti–amyloid‐β therapy
- White matter hyperintensities in Alzheimer's disease in the era of anti‐amyloid therapies